These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 8804514)

  • 21. Treatment of hormone refractory prostate cancer.
    Knox JJ; Moore MJ
    Semin Urol Oncol; 2001 Aug; 19(3):202-11. PubMed ID: 11561988
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bone-targeted therapy: phase II study of strontium-89 in combination with alternating weekly chemohormonal therapies for patients with advanced androgen-independent prostate cancer.
    Amato RJ; Hernandez-McClain J; Henary H
    Am J Clin Oncol; 2008 Dec; 31(6):532-8. PubMed ID: 19060583
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunological monitoring during combination of patient-oriented peptide vaccination and estramustine phosphate in patients with metastatic hormone refractory prostate cancer.
    Noguchi M; Itoh K; Suekane S; Morinaga A; Sukehiro A; Suetsugu N; Katagiri K; Yamada A; Noda S
    Prostate; 2004 Jun; 60(1):32-45. PubMed ID: 15129427
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Oral estramustine and cyclophosphamide in patients with metastatic hormone refractory prostate carcinoma: a phase II study.
    Bracarda S; Tonato M; Rosi P; De Angelis V; Mearini E; Cesaroni S; Fornetti P; Porena M
    Cancer; 2000 Mar; 88(6):1438-44. PubMed ID: 10717628
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Experiences with estramustine phosphate (Estracyt, Emcyt) in prostate cancer.
    Murphy GP; Slack NH; Mittelman A
    Semin Oncol; 1983 Sep; 10(3 Suppl 3):34-42. PubMed ID: 6364365
    [No Abstract]   [Full Text] [Related]  

  • 26. Paclitaxel plus estramustine in metastatic hormone-refractory prostate cancer.
    Hudes GR; Nathan FE; Khater C; Greenberg R; Gomella L; Stern C; McAleer C
    Semin Oncol; 1995 Oct; 22(5 Suppl 12):41-5. PubMed ID: 7481860
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Chemotherapy combination shows efficacy in hormone-refractory prostate cancer.
    Oncology (Williston Park); 1999 Jul; 13(7):1014. PubMed ID: 10442347
    [No Abstract]   [Full Text] [Related]  

  • 28. Matrix metalloproteinase inhibitor Ro 28-2653 in combination with estramustine: tumor-reducing effects on hormone-sensitive prostate cancer in rats.
    Abramjuk C; Jung K; Krell HW; Juchem R; Peters R; Taymoorian K; Staack A; Stephan C; Schnorr J; Loening SA; Lein M
    Anticancer Drugs; 2005 Sep; 16(8):855-61. PubMed ID: 16096433
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Estramustine potentiates taxane in prostate and refractory breast cancers.
    Hamilton A; Muggia F
    Oncology (Williston Park); 2001 May; 15(5 Suppl 7):40-3. PubMed ID: 11396364
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Unique synergism or antagonism of combinations of chemotherapeutic and hormonal agents in human prostate cancer cell lines.
    Kreis W; Budman DR; Calabro A
    Br J Urol; 1997 Feb; 79(2):196-202. PubMed ID: 9052470
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bisphosphonate therapy for hormone refractory prostate cancer with bone metastasis.
    Asahi H; Mizokami A; Maeda Y; Komatsu K; Koshida K; Namiki M
    J Urol; 2003 Jan; 169(1):281-2. PubMed ID: 12478161
    [No Abstract]   [Full Text] [Related]  

  • 32. Estramustine phosphate sodium.
    Hauser AR; Merryman R
    Drug Intell Clin Pharm; 1984 May; 18(5):368-74. PubMed ID: 6373212
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Current studies with docetaxel in hormone-refractory prostate cancer: selected presentations from the 27th European Society for Medical Oncology Congress, 2002.
    DeGrendele H
    Clin Prostate Cancer; 2003 Mar; 1(4):212-4. PubMed ID: 15040878
    [No Abstract]   [Full Text] [Related]  

  • 34. Novel concept of antisurvival factor (ASF) therapy produces an objective clinical response in four patients with hormone-refractory prostate cancer: case report.
    Koutsilieris M; Tzanela M; Dimopoulos T
    Prostate; 1999 Mar; 38(4):313-6. PubMed ID: 10075011
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibition of prostate cancer growth by vinblastine and tamoxifen.
    Pienta KJ; Replogle T; Lehr JE
    Prostate; 1995 May; 26(5):270-4. PubMed ID: 7753712
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Oral chemotherapy in the treatment of hormone-refractory prostate cancer.
    Pienta KJ; Kamradt JM; Smith DC
    Drugs; 1999; 58 Suppl 3():127-31. PubMed ID: 10711851
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Primary breast diffuse large B-cell lymphoma developing subsequent to estramustine therapy for prostate cancer].
    Goto M; Kitamura N; Tanaka A; Katsuragi T; Higashi T; Morimoto H; Shimajiri S; Tsukada J
    Rinsho Ketsueki; 2017; 58(12):2411-2413. PubMed ID: 29332876
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Penile metastasis of prostatic adenocarcinoma.
    Senkul T; Karademir K; Silit E; Işeri C; Erden D; Baloğlu H
    Int J Urol; 2002 Oct; 9(10):597-8. PubMed ID: 12445240
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The treatment of disseminated prostate cancer with estramustine.
    Rosenthal MA; Raghavan D; Stuart-Harris R; Ackland S; Grygiel J
    Aust N Z J Surg; 1992 Nov; 62(11):871-3. PubMed ID: 20169706
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Current status of cytotoxic chemotherapy in hormone refractory prostate cancer.
    Heidenreich A; von Knobloch R; Hofmann R
    Eur Urol; 2001 Feb; 39(2):121-30. PubMed ID: 11223670
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.